Treatment of menstrual migraine

Franco Granella, Grazia Sances, G.L. Messa, M De Marinis, G. C. Manzoni
In: Cephalalgia · 1997 · vol. 17(20_suppl) , pp. 35–38 · doi:10.1177/0333102497017s2011 · PMID:9496777 · W2403834006
review OA: closed CC0 ⤵ 1 in-corpus citation
View on OpenAlex View on PubMed View at publisher
⚙ AI-generated summary by gemini-2.5-flash-lite, 2026-06-06 ⓘ

This paper describes a sequential treatment approach for menstrual migraine, including acute attack drugs, intermittent prophylaxis, and hormonal interventions like oestrogen supplementation or antioestrogen agents.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

Abstract

Because of its pathophysiological and clinical peculiarities, true menstrual migraine (MM) (i.e. migraine starting exclusively between the days immediately before and immediately after the first day of the menstrual cycle) requires an ad hoc management different from that of other migraines. The paucity of well-conducted, controlled clinical trials and the lack of a universally accepted definition of MM have meant that the treatment of MM is still largely empirical. In our clinical practice, we adopt a sequential therapeutic approach, including the following steps: (i) acute attack drugs (sumatriptan, ergot derivatives, NSAIDs); (ii) intermittent prophylaxis with ergot derivatives or NSAIDs; (iii) oestrogen supplementation with percutaneous or transdermal oestradiol (100 microg patches); (iv) antioestrogen agents (danazol, tamoxifen).

My notes (saved in your browser only)

Citation neighborhood (sparse)

Too few in-corpus citations on either side for a chart; here are the lists.

Cites (2)

Cited by (1)

References (20)

Cited by (1)

Source provenance

openalex
last seen: 2026-05-13T17:56:30.163980+00:00
License: CC0 · commercial use OK